By Saadia Aslam Major bleeding that requires hospitalisation occurs in 2% to 3.5% of patients that take DOACs. Some of these patients may require reversal…
View More Reversal agents for DOACs – a recent meta-analysis
Tag: Risk
MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes
Summary taken directly from the American College of CardiologyWritten by: Debabrata Mukherjee, MD, FACC Quick Takes Transseptal MViV in selected patients at high surgical risk…
View More MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes